On September 3, HUTCHMED rose 8.36% in regular trading, trading at HK$21.92/share, with turnover of HK$59.399 million. The rally was driven by the announcement of a landmark exclusive licensing agreement with GlaxoSmithKline for the global development and commercialization of HMPL-A830.

According to the announcement, HUTCHMED's wholly-owned subsidiary has entered into an exclusive development and licensing agreement with a GSK affiliate, granting GSK worldwide rights to develop and commercialize HMPL-A830 outside mainland China, Hong Kong, Macau, and Taiwan. HMPL-A830 is a first-in-class KRAS-EGFR antibody drug conjugate, with clinical development expected to commence in the second half of the year. Initial indications will focus on colorectal cancer, pancreatic cancer, and lung cancer.

Under the agreement terms, HUTCHMED will receive an upfront payment of US$110 million, with potential milestone payments of up to approximately US$1.3 billion and additional tiered royalties based on net sales performance. The total potential transaction value reaches up to US$1.295 billion, providing both near-term cash flow support and long-term revenue upside.

For context, HUTCHMED reported H1 revenue of US$278 million, largely flat year-over-year. Analysts at UBS and SWS Research both maintain Buy ratings on the stock, citing continued overseas expansion of fruquintinib as a core growth driver.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)